Obesity - Lack of Reimbursement Limits Market Potential

Datamonitor predicts a somewhat enthusiastic uptake of two agents currently in development by 2015. However, reimbursement is critical to the uptake of new medication, due to the high cost of therapy. If the reimbursable status is not achieved, the expansion of the market will not match the rate of growth of the obese population and the great potential of the obesity market will remain untapped.

The obesity epidemic is taking place to a certain extent in all the major markets, and the rate of obesity prevalence growth is not showing any signs of slowing down in the near future.

The anti-obesity market growth does not follow the growth of obesity prevalence. The major cause for the lack of growth in most of the major markets is lack of reimbursement for pharmacological management of obesity.

The drugs currently available in the major markets for treatment of obesity have significant unmet needs and do not meet the expectations of obese patients. The pipeline drugs will be able to expand the market. However, the growth of the market will still be marginal in comparison to the growth of obesity prevalence.

Read more...

• Obesity Drug Markets (14/10/2008)
• Valuing Pharmaceutical Innovation (14/10/2008)
• Type 2 Diabetes (15/05/2008)

• Migraine (27/05/2008)
• Gynecological Cancers (27/05/2008)
• Pricing and Reimbursement in Oncology (27/05/2008)

• Therapeutic Cancer Vaccines (27/05/2008)
• Antibacterials (26/05/2008)
• Alzheimer's Disease (26/05/2008)
• Biosimilars: Benchmarking the key players (26/05/2008)
• Atherosclerosis (26/05/2008)
• Melanoma (26/05/2008)
• Respiratory Syncytial Virus (RSV) (26/05/2008)
• Multiple Sclerosis (26/05/2008)
• Osteoarthritis (26/05/2008)

---